Sakura, Kazuma
Kuroyama, Muneyoshi
Shintani, Yasushi
Funaki, Soichiro
Atagi, Shinji
Kadota, Yoshihisa
Kuribayashi, Kozo
Kijima, Takashi
Nakano, Takashi
Nakajima, Toshihiro
Sasai, Masao
Okumura, Meinoshin
Kaneda, Yasufumi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: a clinical trial
https://doi.org/10.1007/s00262-024-03815-1
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP16ck0106127, JP16ck0106127, JP16ck0106127, JP16ck0106127)
Osaka University
Article History
Received: 11 April 2024
Accepted: 17 August 2024
First Online: 3 October 2024
Declarations
:
: The authors declare that they have no conflict of interest.
: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Osaka University Hospital (IRB approved number 157908 and date of approval 25 Oct 2015) for studies involving humans.
: Informed consent was obtained from all participants involved in the study.